A Bispecific Immunotherapy for the Treatment of Melanoma
Published: | Updated:
Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
Mark R. Middleton, MD, PhD
Articles by Mark R. Middleton, MD, PhD
Latest Updated Articles
A Bispecific Immunotherapy for the Treatment of MelanomaPublished: April 24th 2015 | Updated: December 20th 2020